Role of Serum HMGB1 in Prostate Cancer

Mehmet Solakhan; Hülya Çiçek; Necla Benlier; Zeliha Yıldırım; Özlem Nuray Sever; Nuri Orhan; Mustafa Yıldırım

doi:10.5152/eurjther.2019.190052

Authors

Mehmet Solakhan Department of Urology, Bahçesehir University School of Medicine, Medicalpark Gaziantep Hospital, Gaziantep https://orcid.org/0000-0001-9123-9196
Hülya Çiçek Department of Medical Biochemistry, Gaziantep University School of Medicine, Gaziantep https://orcid.org/0000-0003-1045-9619
Necla Benlier Department of Medical Pharmacology, Sanko University School of Medicine, Gaziantep https://orcid.org/0000-0002-8008-0658
Zeliha Yıldırım Department of Veterinary, Gaziantep University Islahiye Vocational School, Gaziantep https://orcid.org/0000-0001-5224-6553
Özlem Nuray Sever Department of Internal Medicine, Medical Oncology, Gaziantep University School of Medicine, Gaziantep https://orcid.org/0000-0003-3462-9360
Nuri Orhan Department of Biochemistry, Medicalpark Gaziantep Hospital, Gaziantep https://orcid.org/0000-0003-1814-8874
Mustafa Yıldırım Department of Internal Medicine, Medical Oncology, Bahçesehir University School of Medicine, Medicalpark Gaziantep Hospital, Gaziantep https://orcid.org/0000-0002-4479-8136

DOI:

https://doi.org/10.5152/eurjther.2019.190052

Keywords:

Diagnosis, HMGB1, prostate carcinoma, prostatitis, PSA

Abstract

Objective: In our study the diagnostic role of HMGB1 levels measured in serum were investigated in prostatitis and prostate carcinoma diagnosis and in the differential diagnosis of these two diseases.
Methods: Patients followed up for histopathologically verified diagnosis of prostate carcinoma and prostatitis in 2014-2017 at the Medicalpark Hospital Urology Clinic were included. HMGB1 measure-ment in serum was performed with the ELISA method.
Results: A total of 78 subjects were included in the study, consisting of 30 (38.5%) prostatitis patients, 25 (32%) prostate carcinoma patients and 23 (29.5%) healthy subjects. HMGB1 was detected as 11.9±2.6 (Range 6.7-18.4) ng/mL in the prostatitis group, 15.1±4.5 (Range 8.4-24.8) ng/mL in the pros-tate carcinoma patients and as 9.2±3.1 (Range 4.7-18.7) ng/mL in the control group. The difference between the groups were investigated using the Friedman test as HMGB1 did not show normal distri-bution. Significant difference was detected between the three groups (p<0.001). When the groups were compared in pair, significant difference was detected between the prostatitis group and the control group (p=0.001). Significant difference was again detected between
the prostate carcinoma group and the control group (p<0.001). Significant difference was detected between the prostatitis group and the prostate carcinoma group (p=0.006). Measurement of serum total prostate specific an-tigen (tPSA) levels were conducted automatically with the electro chemiluminescent method. A mod-erate level of (r=0.276) but a highly significant (p=0.009) positive correlation was found between PSA and HMGB1.
Conclusion: In our study we showed that high PSA and high HMGB1 were highly correlated. HMGB1 measured in serum could be a useful marker in the differentiation of prostatitis and prostate carcino-ma, in the early diagnosis of suspected prostate carcinoma and that HMGB1 value was significantly high in prostate carcinoma patients.

Metrics

Metrics Loading ...

References

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2018; 68: 7-30.

Mohler JL, Antonarakis ES. NCCN Guidelines Updates: Management of Prostate Cancer. J Natl Compr Canc Netw 2019; 17: 583-6.

Kappen S, Jürgens V, Freitag MH, Winter A. Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists. Cancer Manag Res 2019; 11: 3079-97.

Kogan MI, Naboka YL, Ismailov RS, Belousov II, Gudima IA. Bacterial prostatitis: epidemiology and etiology. Urologiia. 2018; 144-8.

Decaestecker K, Oosterlinck W. Transurethral resection of the prostate in recurrent acute bacterial prostatitis. Urol Int 2015; 94: 442-4.

Zhang J, McCauley MJ, Maher LJ 3rd, Williams MC, Israeloff NE. Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res 2009; 37: 1107-14.

Vijayakumar EC, Bhatt LK, Prabhavalkar KS. High Mobility Group Box-1 (HMGB1): A potential target in therapeutics. Curr Drug Targets 2019.

Kargı A, Demirpençe Ö, Gündüz Ş, Göktaş S, Alikanoğlu AS, Yıldırım M. Levels of HMGB1 have a diagnostic role in metastatic renal cell cancer. Cancer Biomarkers 2016; 17: 17-20.

Neupane S, Steyerberg E, Raitanen J, Talala K, Pylväläinen J, Taari K, et al. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. Int J Urol 2017.

Gandaglia G, Albers P, Abrahamsson PA, Briganti A, Catto JWF, Chapple CR, et al. Structured population-based prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. Eur Urol 2019; 76: 142-50.

Buddingh KT, Maatje MGF, Putter H, Kropman RF, Pelger RCM. Do antibiotics decrease prostate-specific antigen levels and reduce the need for prostate biopsy in type IV prostatitis? A systematic literature review. Can Urol Assoc J 2018; 12: E25-30.

Cámara-Quílez M, Barreiro-Alonso A, Rodríguez-Bemonte E, Quindós-Varela M, Cerdán E, Lamas-Maceiras M. Differential characteristics of HMGB2 versus HMGB1 and their perspectives in ovary and prostate cancer. Curr Med Chem 2020; 27: 3271-89.

Tripathi A, Shrinet K, Kumar A. HMGB1 protein as a novel target for cancer. Toxicol Rep 2019; 6: 253-61.

Alsousi AA, Igwe OJ. Redox-active trace metal-induced release of high mobility group box 1(HMGB1) and inflammatory cytokines in fibroblast-like synovial cells is Toll-like receptor 4 (TLR4) dependent. Biochim Biophys Acta Mol Basis Dis 2018; 1864: 3847-58.

Li T, Gui Y, Yuan T, Liao G, Bian C, Jiang Q, et al. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy. BJU Int 2012; 110: E1125-30.

Gnanasekar M, Kalyanasundaram R, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A. HMGB1: A Promising Therapeutic Target for Prostate Cancer. Prostate Cancer 2013; 2013: 157103.

Zhang J, Shao S, Han D, Xu Y, Jiao D, Wu J, et al. High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancerPC3 cells via the RAGE/NF-κB signaling pathway. Int J Oncol 2018; 53: 659-71.

Zhao CB, Bao JM, Lu YJ, Zhao T, Zhou XH, Zheng DY, et al. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res 2014; 4: 369-77.

Xue R, Xu J, Ma S, Jia Z, Yang J. High-mobility group box 1 is involved in the development of benign prostatic hyperplasia with chronic prostatic inflammation. Scand J Urol 2015; 6: 1-7.